|Inquiry into Eli Lilly's practices |
David Teather in New York
Friday March 26, 2004
Eli Lilly, the US pharmaceutical firm, yesterday said US prosecutors were investigating the company's marketing practices for certain of its best selling
The company said the US attorney in its home state of Pennsylvania had informed it of the inquiry in the past few days.
An Eli Lilly spokeswoman said the company understood the investigation was focused on Prozac and two other products, Evista, which fights osteoporosis, and Zyprexa, the world's leading schizophrenia medicine. Zyprexa was the company's highest selling product last year, generating revenues of $4.3bn.
Eli Lilly has been under investigation by the US department of justice since 2002 for its methods of marketing Evista to doctors. The justice department issued a second subpoena for documents related to Evista in July.
Pennsylvania officials recently filed a lawsuit against 13 drug companies, alleging that they offered doctors kickbacks for prescribing.
Medicine and health
British Medical Association
Department of Health
General Medical Council
Health on the Net Foundation
Institute of Cancer Research
Medical Research Council
World Health Organisation
Printable version | Send it to a friend | Save story